Discussion: The QSP platform predicts strong and complex genotypedependent interactions with aripiprazole, risperidone, haloperidol and paliperidone and to a much smaller degree with olanzapine, quetiapine and clozapine. These predictions could in principle be verified in clinical setting and could lead to rational personalized treatment guidance An earlier age of onset negates the protective effects of more mature psychosocial and individual variables, thus the potential for worse outcomes. Genetic variations in this relationship are important to understand as this will allow not only a better understanding of the biological interaction of cannabis and psychosis, but would inform future genetic approaches to risk identification as well. We uniquely examined the mediation of this association (gene x cannabis associations in age of onset of psychosis (AoP)) in 3 genetic variants which, while each have been examined separately, not in combination in the same population. We examined: 1) COMT Val158Met (rs4680) 2) BDNF Val66Met (rs6265) and 3) the AKT1 variant rs2494732. Methods: 168 subjects with a diagnosis of psychosis were recruited from 2 sites in Canada, Edmonton Alberta and Halifax Nova Scotia. Cannabis use data (age at first and regular use) were collected using an electronic self-report survey (to address potential minimization of use to a researcher) and saliva samples were used for genotyping. Kaplan-Meier and Cox regression analyses were used to study the gene -cannabis effects.
F190. EFFECT OF SELECTED GENE VARIANTS ON THE RELATIONSHIP BETWEEN EARLY CANNABIS USE AND AGE OF ONSET OF PSYCHOSIS
Background: Cannabis use, particularly regular use in adolescence, is associated with an increased risk of developing psychosis earlier.
An earlier age of onset negates the protective effects of more mature psychosocial and individual variables, thus the potential for worse outcomes. Genetic variations in this relationship are important to understand as this will allow not only a better understanding of the biological interaction of cannabis and psychosis, but would inform future genetic approaches to risk identification as well. We uniquely examined the mediation of this association (gene x cannabis associations in age of onset of psychosis (AoP)) in 3 genetic variants which, while each have been examined separately, not in combination in the same population. We examined: 1) COMT Val158Met (rs4680) 2) BDNF Val66Met (rs6265) and 3) the AKT1 variant rs2494732. Methods: 168 subjects with a diagnosis of psychosis were recruited from 2 sites in Canada, Edmonton Alberta and Halifax Nova Scotia. Cannabis use data (age at first and regular use) were collected using an electronic self-report survey (to address potential minimization of use to a researcher) and saliva samples were used for genotyping. Kaplan-Meier and Cox regression analyses were used to study the gene -cannabis effects.
Results:
In those who had used cannabis, first use of cannabis prior to 20 years of age was associated with earlier AoP (p = .005). In those who used cannabis before age 20, rs4680 had a trend level association with AoP (log rank test: p=0.0617). A trend effect for an rs6265 x gender interaction (HR = 2.08, p = 0.067) on AoP, controlling for regular cannabis use was also observed. No association was observed between rs2494732 and rs6265 -rs2494732 interaction, and AoP. Discussion: The trends in our associations are in keeping with previous literature, however our gender analyses underscores the importance of examining sex and gender as we further move towards risk identification for the cannabis and psychosis interaction. Our results also suggest that not all genetic variants associated with psychosis are involved with the association between cannabis and AoP. 
Parnassia Group
Background: Treatment with antipsychotics can provoke drug-related movement disorders (DRMD) (also known as extrapyramidal symptoms (EPS)), i.e. tardive dyskinesia (TD), parkinsonism, akathisia and tardive dystonia. DRMD remain a cause for concern in the treatment of patients with psychotic disorders, especially because the DRMD can become irreversible (Correll and Schenk, 2008) . There are lower percentages in younger patients (32%) (Mentzel 2017), but the prevalence is substantial in chronic patients (68% The aim of this umbrella review is to provide clinicians and patients with evidence-based information regarding the genes that are thought to be associated with DRMD and to use this umbrella review on the genetics of DRMD as a basis for recommendations for future prevention programs and research. Methods: To identify all relevant meta-analyses a Medline, Embase, and Psychinfo literature search was performed. Titles and abstract were screened using predetermined criteria by two independent authors. The methodological quality of included meta-analyses was assessed by two overview authors using 'assessment of multiple systematic reviews' (AMSTAR) critical appraisal checklist. Reference lists of included papers and those of reviews were cross-checked and no new publications were found. Results: The search yielded 14 meta-analysis studies and consensus was obtained. The DRD3, DRD2, CYP2D6, 5-HT2A, COMT and MnSOD genes all contain variants that increase the odds ratio of TD. However meta-analyses showed diminishing significance over time and meta-analyses on the same subject were difficult to compare due to differences in patient population and methods used. Discussion: For now it appears that TD is a complex disease with multiple genes that are involved in its phenotype and more studies (eg. Genome wide associatio studies), on a larger scale, are required to develop a genetic test kit to predict the chance of TD. To achieve this multiple research groups need to work together, a DRMD genetic database needs to be in place to overcome publication bias and results need to be stratified by patient characteristics. The result could be test that undoubtedly will be of great clinical value in treating patients and by prospectively preventing debilitating DRMD. 
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